Non-significant differences were observed between TILT-517 monotherapy and its respective combinations with anti-PD-1 or anti-PDL-1, thus indicating that the combination treatments neither enhanced nor reduced the tumor cell killing effect. This evidence concerns the gene CD274 and neoplasm.